Karen Kelly
Hematology & Oncology · Sacramento, CANPI 1477651222
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $126,263 of the $147,640 with a category attached, or 85.5%. It is spread thinly across 22 manufacturers, the largest accounting for just 20.1%. Reporting peaked in 2020 at $62,102 and has fallen 92.3% since, to $4,778 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $1330.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$30K
- EMD Serono, Inc.$24K
- Astrazeneca UK Limited$11K
- Novartis$10K
- Amgen$8K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- plus $56K from 16 others
Across 348 payments — averaging $6364.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1M
- EMD Serono, Inc.$375K
- Genentech, Inc.$283K
- E.r. Squibb & Sons, L.L.C.$214K
- Novartis$96K
- Regeneron$56K
- plus $154K from 5 others
What the payments were for
- Royalty or licence$4,8103%
- Consulting fees$126,26386%
- Speaking & faculty fees$6300%
- Travel & lodging$13,9859%
- Food & beverage$1,9521%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $29,704 |
| EMD Serono, Inc. | 13 | $24,356 |
| Astrazeneca UK Limited | 7 | $10,551 |
| Novartis | 7 | $10,392 |
| Amgen | 5 | $8,294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $8,200 |
| Sanofi | 3 | $8,045 |
| Genentech USA, Inc. | 5 | $6,656 |
| AbbVie | 5 | $6,253 |
| Merck | 8 | $5,801 |
| Eli Lilly | 11 | $5,031 |
| Janssen Scientific Affairs, LLC | 4 | $4,040 |
| Bard Peripheral Vascular, Inc. | 3 | $3,595 |
| Regeneron | 3 | $3,351 |
| Merck Kgaa | 1 | $3,000 |
| Regeneron Healthcare Solutions, Inc. | 2 | $2,761 |
| E.r. Squibb & Sons, L.L.C. | 7 | $2,625 |
| Daiichi Sankyo Inc. | 2 | $2,368 |
| Genentech, Inc. | 4 | $1,347 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $1,215 |
| Jazz Pharmaceuticals Inc. | 1 | $41 |
| Nalu Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$147,640 in reported general payments places this provider in the 90th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Sacramento
- Nitin RohatgiSacramento$814K
- Mehrdad AbediSacramento$613K
- Adam GiermaszSacramento$438K
- Scott ChristensenSacramento$349K
- David GandaraSacramento$336K
- Joseph TuscanoSacramento$258K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.